Phone: 1.510.856.5600|

Press Releases

Press Releases
  Date Title and Summary View
Nov 4, 2016
Blisibimod topline data from the Phase 3 CHABLIS-SC1 Study in severe lupus patients is imminentData and Safety Monitoring Board recommendation to continue SOLUTION study with Sollpura™FDA Type C meeting in September validated basis for BLA filing and manufacturing approach for Sollpura™Closing of initial $17 million registered direct of...
Nov 2, 2016
HAYWARD, Calif., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced that an abstract of the interim data from the Phase 2 BRIGHT-SC clinical study evaluating the treatment effect of blisibimod in patients with biopsy-proven IgA Nephropathy (IgAN) has been accepted as a late-breaking poster presentation a...
Nov 1, 2016
Sep 8, 2016
HAYWARD, Calif., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that it has agreed to sell preferred convertible stock in two tranches to Biotechnology Value Fund, L.P. and other affiliates of BVF Partners L.P. ("BVF"), and Rock Springs Capital for initial proceeds of $17.0 million with an option fo...
Aug 16, 2016
HAYWARD, Calif., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced the appointment of William Shanahan, M.D., J.D. as Chief Medical Officer.  In his role as Chief Medical Officer, Dr. Shanahan will bring his experience as a Rheumatologist and in drug development to lead the blisibimod lupus program and ...
Aug 16, 2016
HAYWARD, Calif., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced that the Data and Safety Monitoring Board (DSMB) completed its first pre-planned safety review of the Phase 3 SOLUTION clinical study of Sollpura™ in cystic fibrosis patients with exocrine pancreatic insufficiency. The DSMB had "no...
Aug 9, 2016
Met enrollment target in SOLUTION study and enrolled first patient in SIMPLICITY study of Sollpura™Successful sachet manufacturing to support SIMPLICITY study and commercial-scale lipase demonstration batchFirst patient enrolled in pivotal CHABLIS 7.5 clinical study of blisibimodPositive trends from analysis of BRIGHT-SC Phase 2 clinical stud...
Aug 3, 2016
HAYWARD, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that the last patient in the Phase 3 CHABLIS-SC1 clinical study, evaluating blisibimod for the treatment of systemic lupus erythematosus, received their final study dose on July 27th.  As described in the protocol, patients are followed ...
Jun 28, 2016
Positive trends from BRIGHT-SC proof-of-concept study - study to continueSOLUTION study with Sollpura completed patient screening ahead of schedule - data in 2016First patients screened in Phase 3 CHABLIS 7.5 study of blisibimod in seropositive lupus patientsCHABLIS-SC1 results to be reported in the third quarter.  Recent DSMB review found no safet...
Jun 15, 2016
Page: FirstPrevious
... NextLast
= add release to Briefcase
Print Friendly